🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 112 of 151

  1. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

  2. S-Amlodipine TAB (VAM) 1.25 mg, Amlodipine 2.5 mg

    Zentiva k.s.

    Patients with moderate or severe oedema on a long-term treatment with amlodipine

    phase 2 small molecule active

    1 trial

  3. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  4. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  5. S095035

    Tango Therapeutics

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  6. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  8. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

  9. S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion.

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  10. SA-ER 500 mg

    Ultragenyx UK Limited

    GNE Myopathy

    phase 2 small molecule completed

    1 trial

  11. SA55 Injection

    Sinovac Research and Development Co.,

    Infection of Upper Respiratory Tract Caused by 2019-nCoV

    phase 2 small molecule active

    1 trial

  12. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  13. SAB-176

    SAB Biotherapeutics

    Influenza A H1N1

    phase 2 mab completed

    1 trial

  14. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  15. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  16. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Mild Cognitive Impairment

    phase 2 small molecule completed

    1 trial

  17. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington Disease

    phase 2 small molecule completed

    2 trials

  18. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  20. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  21. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  22. SALBUTAMOL, FLUTICASONE PROPIONATE, NVA237, NVA237, SALMETEROL XINAFOATE, The Placebo is a generic Placebo, inhalation powder, hard capsule. It is used to match an active dosage forms (NVA237 12.5µg and NVA 237 25µg) in this clinical trial. The placebo comprises inactive excipients (magnesium stearate and lactose monohydrate) encapsulated in hard non-gelatin capsules matching those used for the active drug product.

    Novartis Pharmaceuticals

    Asthma

    phase 2 small molecule active

    1 trial

  23. SALINE, OTHER PLASMA PROTEIN FRACTIONS , Octaplasma 45-70 mg/ml pulver og væske til infusjonsvæske, oppløsning, Saline (NaCl)

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  24. SAR421869

    Sanofi-aventis Healthcare Pty Ltd

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  25. SAR422459

    Sanofi-aventis Healthcare Pty Ltd

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  26. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  27. SAR440340

    Sanofi Pasteur

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  28. SAR440340

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  29. SAR440340

    Regeneron UK Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  30. SAR441566

    Sanofi Pasteur

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  31. SAR442970

    Sanofi Pasteur

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  32. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  33. SAR443122

    Sanofi Pasteur

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  34. SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  35. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

  36. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi-aventis Healthcare Pty Ltd

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  37. SAR444656 (KT-474)

    Kymera Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule terminated

    1 trial

  38. SAR444656 (KT-474)

    Kymera Therapeutics

    Atopic Dermatitis

    phase 2 small molecule terminated

    1 trial

  39. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  40. SAR444881

    Regeneron UK Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  41. SAR445761 - belumosudil, belumosudil

    Sanofi-aventis Healthcare Pty Ltd

    Chronic graft versus host disease.

    phase 2 small molecule active

    1 trial

  42. SAR447537

    Sanofi Pasteur

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule active

    1 trial

  43. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  44. SARCLISA 20mg/mL concentrate for solution for infusion., CellProtect

    The George Institute

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  45. SARS-CoV-2 convalescent plasma

    United Therapeutics Europe Ltd

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  46. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  47. SB-318

    SANGAMO THERAPEUTICS, INC

    MPS I

    phase 2 mab terminated

    1 trial

  48. SB-509

    SANGAMO THERAPEUTICS, INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.